Oppenheimer cut shares of Nektar Therapeutics (NASDAQ:NKTR – Get Rating) from an outperform rating to a market perform rating in a research note published on Monday, The Fly reports. Oppenheimer also issued estimates for Nektar Therapeutics’ FY2022 earnings at ($2.94) EPS, FY2023 earnings at ($2.49) EPS, FY2024 earnings at ($2.22) EPS and FY2025 earnings at […]
/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Cash and.
/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021. Cash and investments in.
Nektar Therapeutics Reports Second Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.